Company: INKT
Filing Date: 2025-08-22
Form Type: 424B5
Source: 0001193125-25-186417
Chunk: 1

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-08-22
Form: 424B5
Chunk 1
---
 subject to the limitations of such General Instruction I.B.6 in the future, we will file another supplement to the ATM Prospectus.

Through August 21, 2025, we have offered and sold 478,462 shares of common stock for gross proceeds of $13,414,485 pursuant to the Agreement.
Accordingly, because we are no longer subject to the sales limitations of such General Instruction I.B.6, we may offer and sell up to an additional $36,585,515 of shares of common stock pursuant to the Agreement.

Our common stock is listed on the Nasdaq Capital Market under the symbol “INKT”. On August 21, 2025, the last reported sale price of our
common stock on the Nasdaq Capital Market was $14.95 per share.

You should read carefully and consider the “Risk Factors” referenced on page S-5of the ATM Prospectus and the risk factors described in other documents incorporated by reference herein.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

Sole Sales Agent

B. Riley Securities

The date of this prospectus supplement is August 22, 2025.